for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sarepta Therapeutics Inc

SRPT.OQ

Latest Trade

90.32USD

Change

0.42(+0.47%)

Volume

1,097,530

Today's Range

89.50

 - 

92.79

52 Week Range

78.06

 - 

181.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
89.90
Open
90.19
Volume
1,097,530
3M AVG Volume
33.99
Today's High
92.79
Today's Low
89.50
52 Week High
181.80
52 Week Low
78.06
Shares Out (MIL)
78.91
Market Cap (MIL)
7,127.43
Forward P/E
-13.43
Dividend (Yield %)
--

Next Event

Q4 2020 Sarepta Therapeutics Inc Earnings Release

Latest Developments

More

Sarepta Therapeutics And Genevant Sciences Announce Research Collaboration For Lipid Nanoparticle-Based Gene Editing Therapeutics

Sarepta Announces Top-Line Results For Part 1 Of Study 102 Evaluating SRP-9001

Sarepta Therapeutics Announces Executive Management Changes

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Industry

Business Services

Contact Info

215 1st St Ste 415

CAMBRIDGE, MA

02142-1213

United States

+1.617.2744000

https://www.sarepta.com/

Executive Leadership

M. Kathleen Behrens

Independent Chairwoman of the Board

Douglas S. Ingram

President, Chief Executive Officer, Director

Ian Michael Estepan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

William F. Ciambrone

Executive Vice President - Technical Operations

Alexander Cumbo

Executive Vice President and Chief Commercial Officer

Key Stats

2.22 mean rating - 23 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.3K

2019

0.4K

2020(E)

0.5K
EPS (USD)

2017

-0.860

2018

-5.460

2019

-9.710

2020(E)

-6.725
Price To Earnings (TTM)
--
Price To Sales (TTM)
14.40
Price To Book (MRQ)
7.98
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
78.52
LT Debt To Equity (MRQ)
78.52
Return on Investment (TTM)
-30.88
Return on Equity (TTM)
-26.79

Latest News

Latest News

Sarepta's shares sink 50% after muscle disorder drug fails to meet main goal

Drugmaker Sarepta Therapeutics Inc said on Thursday its experimental gene therapy to treat a muscle-wasting disorder did not achieve statistical significance in one of the main goals of a study, sending its shares down 50%.

BRIEF-Sarepta Therapeutics Signs Agreement With Hansa Biopharma For Imlifidase

* SAREPTA THERAPEUTICS SIGNS AGREEMENT WITH HANSA BIOPHARMA FOR IMLIFIDASE

BRIEF-Hansa Biopharma Announces Exclusive Agreement With Sarepta Therapeutics

* HANSA BIOPHARMA ANNOUNCES EXCLUSIVE AGREEMENT WITH SAREPTA THERAPEUTICS TO DEVELOP AND PROMOTE IMLIFIDASE AS PRE-TREATMENT AHEAD OF GENE THERAPY IN SELECT INDICATIONS

BRIEF-Sarepta Therapeutics Announces Retirement Of Sandy Mahatme, Chief Financial Officer And Chief Business Officer

* SAREPTA THERAPEUTICS ANNOUNCES RETIREMENT OF SANDY MAHATME, CHIEF FINANCIAL OFFICER AND CHIEF BUSINESS OFFICER

BRIEF-Sarepta Therapeutics And Codiak Biosciences Collaborate To Research And Develop Exosome-Based Therapeutics For Rare Diseases

* SAREPTA THERAPEUTICS AND CODIAK BIOSCIENCES COLLABORATE TO RESEARCH AND DEVELOP EXOSOME-BASED THERAPEUTICS FOR RARE DISEASES

BRIEF-Sarepta Therapeutics Announces Positive Safety & Efficacy Data From SRP-9001 Micro-Dystrophin Gene Therapy Trial Published In JAMA Neurology

* SAREPTA THERAPEUTICS ANNOUNCES POSITIVE SAFETY AND EFFICACY DATA FROM THE SRP-9001 MICRO-DYSTROPHIN GENE THERAPY TRIAL PUBLISHED IN JAMA NEUROLOGY

BRIEF-Sarepta Announces Positive Expression And Functional Data From SRP-9003 Gene Therapy Trial

* SAREPTA THERAPEUTICS ANNOUNCES POSITIVE EXPRESSION AND FUNCTIONAL DATA FROM THE SRP-9003 GENE THERAPY TRIAL TO TREAT LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2E

BRIEF-Sarepta Therapeutics To Share Clinical Update From Srp-9003 Gene Therapy Trial To Treat Limb-Girdle Muscular Dystrophy Type 2E

* SAREPTA THERAPEUTICS TO SHARE CLINICAL UPDATE FROM SRP-9003 GENE THERAPY TRIAL TO TREAT LIMB-GIRDLE MUSCULAR DYSTROPHY TYPE 2E, OR BETA-SARCOGLYCANOPATHY Source text for Eikon: Further company coverage:

BRIEF-Personalis Announces Scientific Collaboration With Sarepta Therapeutics

* PERSONALIS ANNOUNCES SCIENTIFIC COLLABORATION WITH SAREPTA THERAPEUTICS ON IMMUNE RESPONSE TO PRECISION GENETIC THERAPEUTICS

BRIEF-Sarepta Therapeutics And Dyno Therapeutics Announce Agreement To Develop Next-Generation Gene Therapy Vectors For Muscle Diseases

* SAREPTA THERAPEUTICS AND DYNO THERAPEUTICS ANNOUNCE AGREEMENT TO DEVELOP NEXT-GENERATION GENE THERAPY VECTORS FOR MUSCLE DISEASES

BRIEF-Sarepta Therapeutics Announces Research Agreement With U.S. Department Of Defense To Evaluate Multiple Constructs From Its Proprietary Rna Platform As Treatments For Covid-19

* SAREPTA THERAPEUTICS ANNOUNCES RESEARCH AGREEMENT WITH U.S. DEPARTMENT OF DEFENSE TO EVALUATE MULTIPLE CONSTRUCTS FROM ITS PROPRIETARY RNA PLATFORM AS TREATMENTS FOR COVID-19

BRIEF-Lysogene Says Has Financial Visibility Until Q3 Of 2021

* LYSOGENE REPORTS FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE

BRIEF-Sarepta Therapeutics Says CEO Douglas Ingram's 2019 Total Compensation Was $1.4 Mln Versus $1.4 Mln In 2018

* SAREPTA THERAPEUTICS INC SAYS CEO DOUGLAS INGRAM'S 2019 TOTAL COMPENSATION WAS $1.4 MILLION VERSUS $1.4 MILLION IN 2018 – SEC FILING

BRIEF-Sarepta Therapeutics Posts Non-GAAP Loss Per Share Of $1.57

* SAREPTA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

Sarepta shares fall 4% after FDA documents show safety concerns about drug

Shares of Sarepta Therapeutics Inc were down around 4% Wednesday after the U.S. Food and Drug Administration revealed documents detailing concerns it had about the safety and efficacy of one of the company's recently approved Duchenne muscular dystrophy (DMD) drugs.

Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing deal

Roche Holding AG made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States.

BRIEF-Sarepta Therapeutics Announces Partnership With Roche In Territories Outside The United States

* SAREPTA THERAPEUTICS ANNOUNCES PARTNERSHIP WITH ROCHE IN TERRITORIES OUTSIDE THE UNITED STATES FOR ITS INVESTIGATIONAL MICRO-DYSTROPHIN GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY, SRP-9001

Roche enters $1.15 bln licensing deal for Sarepta gene therapy

Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's gene therapy for Duchenne muscular dystrophy (DMD) outside the United States, it said on Monday.

Sarepta shares surge after surprise approval of Duchenne Muscular Dystrophy drug

Shares of Sarepta Therapeutics Inc <SRPT.O> soared 31% on Friday after U.S. regulators shocked Wall Street by approving the company's treatment for a muscle-wasting disorder less than four months after rejecting the drug over safety concerns.

CORRECTED-UPDATE 1-U.S. FDA approves Sarepta's newest DMD treatment (Dec. 12)

The U.S. Food and Drug Administration on Thursday approved Sarepta Therapeutics Inc's second treatment for Duchenne muscular dystrophy (DMD).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up